FeesSafety
Pluang+

Adagene doses first patient in Phase 1 trial of ADG138 for HER2-positive tumors

Market News
19 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
Adagene doses first patient in Phase 1 trial of ADG138 for HER2-positive tumors

Adagene Inc. has dosed the first patient in a Phase 1 clinical trial of ADG138, a novel double-masked HER2×CD3 bispecific T-cell engager designed to target HER2-positive advanced solid tumors. The drug uses proprietary SAFEbody technology to minimize off-target effects and enhance tumor-specific activation, showing promising preclinical results including efficacy in resistant tumor models and reduced side effects. This trial will evaluate ADG138's safety and preliminary efficacy, starting with a 2 mg dose and escalating based on patient response. Success could lead to new treatment options for patients with advanced HER2-positive cancers who have exhausted other therapies.

Adagene's first patient dosing in a Phase 1 study of ADG138 provides context for health sector market data. For readers following health stocks, here is Pluang's market snapshot as of Nov 19, 2026 18:12 WIB: out of 150 priced US health-sector stocks tradable on Pluang, 79 rose and 64 fell. Notable movers include AbCellera Biologics Inc (ABCL) at USD 11.32 with a 1-day change of +2.72% and 100% buy order activity, Sana Biotechnology Inc (SANA) at USD 1.90 with +2.70% change and 60% sell order activity, and BioNano Genomics Inc (BNGO) at USD 0.95 with -2.65% change.

More News

Bath & Body Works beats earnings and revenue estimates, launches $500M buyback, raises sales outlook.

Bath & Body Works beats earnings and revenue estimates, launches $500M buyback, raises sales outlook.

Bath & Body Works reported third-quarter earnings per share of $0.26, surpassing the $0.12 estimate, and revenue of $1.58 billion, above the $1.55 billion estimate. The company also announced a new $500 million share repurchase program and raised its...

Company Fundamentals
Bullish
52 minutes ago
Pasqal integrates quantum processors natively into Slurm for easier HPC management with NVIDIA support.

Pasqal integrates quantum processors natively into Slurm for easier HPC management with NVIDIA support.

Pasqal has integrated its neutral-atom quantum processors natively into Slurm's Hierarchical Resources (HRES) system, recently expanded by NVIDIA. This allows supercomputing centers to manage quantum processing units (QPUs) alongside CPUs and GPUs mo...

Market News
Bullish
56 minutes ago
SpaceX shifts focus from satellite internet profits to rapid AI growth, trading at a high valuation.

SpaceX shifts focus from satellite internet profits to rapid AI growth, trading at a high valuation.

SpaceX currently earns most of its profits from its Starlink satellite internet service, which has 13.6 million subscribers and generated $2.37 billion in operating income last quarter. However, the company is aggressively pivoting towards artificial...

Market News
Bullish
1 hour ago
TSMC and Applied Materials poised for strong growth amid booming semiconductor demand.

TSMC and Applied Materials poised for strong growth amid booming semiconductor demand.

Despite a recent 25% drop in semiconductor stocks, TSMC and Applied Materials stand out due to their dominant market positions and growth potential. TSMC leads with a 73% share in the foundry market, benefiting from AI chip demand and planned price h...

Market News
Bullish
1 hour ago
Stock market faces sharp correction risk amid AI turmoil and rising interest rates, Buffett advises cautious investing.

Stock market faces sharp correction risk amid AI turmoil and rising interest rates, Buffett advises cautious investing.

The stock market is vulnerable to a sharp correction due to rising interest rates and uncertainty in the AI industry following Nvidia CEO Jensen Huang's departure amid scandal. Inflation pressures have led the Federal Reserve to raise rates, potentia...

Bearish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App